(Total Views: 124)
Posted On: 01/19/2024 3:58:51 PM
Post# of 229
NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, announced that CEO Eric A Adams will be participating in the upcoming Water Tower Research Fireside Chat Series. This month’s chat is scheduled to begin at 1 p.m. ET on Jan. 25, 2024. According to the announcement, topics discussed during the event will include an overview of InMed’s pharmaceutical pipeline in Alzheimer’s and ocular as well as a discussion about cannabinoids and their possible role in the treatment of Alzheimer’s. In addition, the chat will include a look at upcoming 2024 milestone in both InMed’s pharmaceutical drug development as well as BayMedica’s health and wellness initiatives. A replay of the webcast will be available to view following the presentation. A shareholder communication and engagement platform powered by senior industry experts with significant Wall Street experience, Water Tower Research is committed to creating, delivering and maintain the information flow required to build and preserve relationships with every stakeholder and potential investor.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://nnw.fm/INM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, announced that CEO Eric A Adams will be participating in the upcoming Water Tower Research Fireside Chat Series. This month’s chat is scheduled to begin at 1 p.m. ET on Jan. 25, 2024. According to the announcement, topics discussed during the event will include an overview of InMed’s pharmaceutical pipeline in Alzheimer’s and ocular as well as a discussion about cannabinoids and their possible role in the treatment of Alzheimer’s. In addition, the chat will include a look at upcoming 2024 milestone in both InMed’s pharmaceutical drug development as well as BayMedica’s health and wellness initiatives. A replay of the webcast will be available to view following the presentation. A shareholder communication and engagement platform powered by senior industry experts with significant Wall Street experience, Water Tower Research is committed to creating, delivering and maintain the information flow required to build and preserve relationships with every stakeholder and potential investor.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://nnw.fm/INM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
